Schering-Plough Corporation

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 3
gptkbp:bfsParent gptkb:Schering_AG
gptkbp:acquired gptkb:Merck_&_Co.
gptkbp:acquisition gptkb:collaboration
multiple companies
November 3, 2009
gptkbp:clinical_trial ongoing
collaborative studies
gptkbp:collaborated_with gptkb:Schering_AG
gptkbp:cultural_representation workforce diversity
gptkbp:dissolved gptkb:2009
gptkbp:employees approximately 26,000
gptkbp:financial_performance financial disclosures
strong revenue growth
gptkbp:founded 1851
gptkbp:founder Friedrich Schering
gptkbp:global_presence over 140 countries
gptkbp:headquarters gptkb:Kenilworth
gptkb:United_States
gptkb:Kenilworth,_New_Jersey
https://www.w3.org/2000/01/rdf-schema#label Schering-Plough Corporation
gptkbp:industry gptkb:drug
gptkbp:invention numerous
gptkbp:investment research and development
publicly traded
shareholder communication
gptkbp:key_people gptkb:Fred_Hassan
gptkbp:language_of_instruction various drugs in development
gptkbp:leadership executive team
gptkbp:market_cap $41 billion (2008)
gptkbp:market_segment pharmaceuticals and consumer health
gptkbp:marketing_strategy global expansion
gptkbp:notable_products gptkb:Claritin
gptkb:Temodar
gptkb:Vytorin
gptkb:Zetia
gptkb:Nexium
gptkbp:parent_company gptkb:Merck_&_Co.
gptkbp:partnerships various biotech companies
gptkbp:philanthropy healthcare initiatives
gptkbp:previous_name gptkb:Schering_Corporation
gptkbp:products drugs
gptkbp:regulatory_compliance FDA approvals
gptkbp:research_and_development biopharmaceuticals
gptkbp:research_areas neurology
oncology
dermatology
infectious diseases
immunology
cardiovascular
gptkbp:revenue $18.5 billion (2008)
gptkbp:social_responsibility community engagement
gptkbp:subsidiary gptkb:Schering_Corporation
gptkbp:sustainability_initiatives environmental responsibility
gptkbp:symbol SGP
gptkbp:type gptkb:Company
gptkbp:website www.schering-plough.com